CLINICAL_TRIALS ClinicalTrials.gov record update

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01960348
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:49.250226+00:00
Published At: 2018-09-06T00:00:00+00:00
Record Updated At: 2024-04-22
Results Posted At: 2018-09-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["TTR-mediated Amyloidosis", "Amyloidosis, Hereditary", "Amyloid Neuropathies, Familial", "Familial Amyloid Polyneuropathies", "Amyloid Neuropathies", "Amyloidosis, Hereditary, Transthyretin-Related"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-04-22"
protocolSection.identificationModule.nctId: "NCT01960348"
protocolSection.identificationModule.officialTitle: "APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-09-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.